10 Best Weight Loss Drug Stocks to Buy in 2026

8. Hims & Hers Health, Inc. (NYSE:HIMS)

Number of Hedge Fund Holders: 43

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the best weight loss drugs on this list.

TheFly reported on June 17 that Barclays maintained its Overweight rating on HIMS while increasing its price target to $39.00 from $29.00. The firm highlighted that growth in weight-loss offerings, along with contributions from other business areas, is expected to drive stronger revenue and EBITDA momentum in the second half of 2026. Barclays also noted that the stock could see further upside as investors gain greater confidence in the company’s future growth trajectory, with its data indicating improving trends following the partnership announcement with Novo Nordisk.

Separately, on June 2, Hims & Hers Health, Inc. (NYSE:HIMS) announced the completion of its acquisition of Eucalyptus, strengthening its global consumer healthcare platform. The acquisition expands HIMS’ reach across key markets, including the United States, the United Kingdom, Australia, and Canada, while supporting further international growth. By combining Eucalyptus’ digital health expertise and regional capabilities with HIMS’ technology platform, the company aims to provide more personalized and accessible healthcare solutions worldwide. The transaction enhances the company’s global presence and supports its long-term growth strategy focused on expanding its healthcare ecosystem, improving customer access, and delivering personalized care at scale.

Hims & Hers Health, Inc. (NYSE:HIMS) is a telehealth company providing digital healthcare services, including weight management treatments. After offering compounded GLP-1 alternatives, it shifted toward branded weight-loss medications through partnerships with major pharmaceutical companies, building a broader metabolic health platform.